Development of a cell-specific AAV production platform (CARE™)
using machine learning-based artificial intelligence (AI) (patent pending)
Development of a platform to develop AAV that improves cell targeting through Meta analysis based on more than 5 billion literature information
Development of new serotype AAVs with improved cell targeting improves drug efficacy and reduces side effects
AAV design for various diseases is possible by controlling AAV's ability to target and de-target cells